Safety, tolerability, efficacy, pharmacokinetics, and pharmacodynamics of the oral TYK2 inhibitor PF-06826647 in participants with plaque psoriasis: a phase 1, randomised, double-blind, placebo-controlled, parallel-group study

[1]  E. Peeva,et al.  Safety and Pharmacokinetics of the Oral TYK2 Inhibitor PF‐06826647: A Phase I, Randomized, Double‐Blind, Placebo‐Controlled, Dose‐Escalation Study , 2020, Clinical and translational science.

[2]  S. Wright,et al.  Discovery of Tyrosine Kinase 2 (TYK2) Inhibitor (PF-06826647) for the Treatment of Autoimmune Diseases. , 2020, Journal of medicinal chemistry.

[3]  E. Peeva,et al.  Molecular and Cellular Responses to the TYK2/JAK1 Inhibitor, PF 06700841, Reveal Reduction of Skin Inflammation in Plaque Psoriasis: TYK2/JAK1 inhibitor in plaque psoriasis. , 2020, The Journal of investigative dermatology.

[4]  M. Suárez-Fariñas,et al.  Short-term transcriptional response to IL-17 Receptor-A antagonism in the treatment of Psoriasis. , 2019, The Journal of allergy and clinical immunology.

[5]  Xiaoyu Jiang,et al.  IL-17A inhibition by secukinumab induces early clinical, histopathological, and molecular resolution of psoriasis. , 2019, The Journal of allergy and clinical immunology.

[6]  Katherine Li,et al.  Modulation of inflammatory gene transcripts in psoriasis vulgaris: Differences between ustekinumab and etanercept. , 2019, The Journal of allergy and clinical immunology.

[7]  M. Gooderham,et al.  Phase 2 Trial of Selective Tyrosine Kinase 2 Inhibition in Psoriasis , 2018, The New England journal of medicine.

[8]  E. H. Thompson,et al.  Efficacy and safety of risankizumab in moderate-to-severe plaque psoriasis (UltIMMa-1 and UltIMMa-2): results from two double-blind, randomised, placebo-controlled and ustekinumab-controlled phase 3 trials , 2018, The Lancet.

[9]  K. Page,et al.  The Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of a TYK2/JAK1 Inhibitor (PF‐06700841) in Healthy Subjects and Patients With Plaque Psoriasis , 2018, Journal of clinical pharmacology.

[10]  C. Pitzalis,et al.  Role of the IL-23/IL-17 Axis in Psoriasis and Psoriatic Arthritis: The Clinical Importance of Its Divergence in Skin and Joints , 2018, International journal of molecular sciences.

[11]  U. Persson,et al.  Real-world outcomes in 2646 psoriasis patients: one in five has PASI ≥10 and/or DLQI ≥10 under ongoing systemic therapy , 2017, The Journal of dermatological treatment.

[12]  G. Goldenberg,et al.  New Oral Therapies for Psoriasis: A Comprehensive Review. , 2016, The Journal of clinical and aesthetic dermatology.

[13]  S. Chimenti,et al.  Apremilast, an oral phosphodiesterase 4 (PDE4) inhibitor, in patients with moderate to severe plaque psoriasis: Results of a phase III, randomized, controlled trial (Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis [ESTEEM] 1). , 2015, Journal of the American Academy of Dermatology.

[14]  M. Corazza,et al.  Low-dose acitretin in treatment of plaque-type psoriasis: descriptive study of efficacy and safety. , 2015, Acta dermato-venereologica.

[15]  Y. Sekine,et al.  Tyk2 is a therapeutic target for psoriasis-like skin inflammation. , 2014, International immunology.

[16]  Y. Wasfi,et al.  Guselkumab (an IL-23-specific mAb) demonstrates clinical and molecular response in patients with moderate-to-severe psoriasis. , 2014, The Journal of allergy and clinical immunology.

[17]  A. Armstrong,et al.  Quality of Life and Work Productivity Impairment among Psoriasis Patients: Findings from the National Psoriasis Foundation Survey Data 2003–2011 , 2012, PloS one.

[18]  Suyan Tian,et al.  Meta-Analysis Derived (MAD) Transcriptome of Psoriasis Defines the “Core” Pathogenesis of Disease , 2012, PloS one.

[19]  B. Strober,et al.  Efficacy and safety of tofacitinib, an oral Janus kinase inhibitor, in the treatment of psoriasis: a Phase 2b randomized placebo‐controlled dose‐ranging study , 2012, The British journal of dermatology.

[20]  R. Langley,et al.  Effective and sustainable biologic treatment of psoriasis: what can we learn from new clinical data? , 2012, Journal of the European Academy of Dermatology and Venereology : JEADV.

[21]  Mayte Suárez-Fariñas,et al.  Effective treatment of psoriasis with etanercept is linked to suppression of IL-17 signaling, not immediate response TNF genes. , 2009, The Journal of allergy and clinical immunology.

[22]  J. Saurat,et al.  Efficacy and safety results from the randomized controlled comparative study of adalimumab vs. methotrexate vs. placebo in patients with psoriasis (CHAMPION) , 2007, The British journal of dermatology.

[23]  Erin G Harper,et al.  Pathophysiology of psoriasis: Recent advances on IL-23 and Th17 cytokines , 2007, Current rheumatology reports.

[24]  Kathleen M. Smith,et al.  IL-23 stimulates epidermal hyperplasia via TNF and IL-20R2–dependent mechanisms with implications for psoriasis pathogenesis , 2006, The Journal of experimental medicine.

[25]  M. Dhodapkar,et al.  Increased Expression of Interleukin 23 p19 and p40 in Lesional Skin of Patients with Psoriasis Vulgaris , 2004, The Journal of experimental medicine.

[26]  W. Dietrich,et al.  A natural mutation in the Tyk2 pseudokinase domain underlies altered susceptibility of B10.Q/J mice to infection and autoimmunity , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[27]  P. Bossuyt,et al.  Methotrexate versus cyclosporine in moderate-to-severe chronic plaque psoriasis. , 2003, The New England journal of medicine.

[28]  I S Chan,et al.  Test‐Based Exact Confidence Intervals for the Difference of Two Binomial Proportions , 1999, Biometrics.